When health insurers buy an existing book of business, they often effect the acquisition through an asset purchase transaction known as assumption reinsurance. There are many accounting and financial issues to consider in pursuing such a transaction.
When health insurers buy an existing book of business, they often effect the acquisition through an asset purchase transaction known as assumption reinsurance. There are many accounting and financial issues to consider in pursuing such a transaction.
Because the transaction involves a transfer by the seller of significant assets as well as liabilities, it is usually appropriate for the buyer to view the transaction as an acquisition of the seller's balance sheet, either in whole or in part.
One of the first considerations deals with whether the buyer will assume the liability for existing incurred losses, or have the seller retain them. Usually, the buyer will want the seller to retain such existing losses so as to minimize its due diligence in analyzing the adequacy of reserves. If the buyer succeeds in having the seller retain the existing losses, the assumption reinsurance agreement will define "excluded" or "retained" liabilities to cover all contractual obligations arising prior to closing, including all known incurred claims, as well as claims incurred but not reported (IBNR). Typically, the seller also will retain responsibility for all extra-contractual obligations related to the issuance of the policies.
OTHER EXPENSES
With respect to other expenses associated with the book of business, the buyer will usually want to draw a bright line as of the closing date and have the seller retain responsibility for expenses related to the business prior to the closing. This division of responsibility should be addressed in the assumption reinsurance agreement and should cover expenses such as agent commissions, premium taxes, guaranty fund obligations and other expenses based on premium volume such as risk pool assessments.
In consideration for the assumption of these liabilities, the assumption reinsurance agreement will call for payment to be made at closing by the seller to the buyer equal to the amount of the reserves.
Typically, the purchase price being paid by the buyer will be netted against this amount. In small transactions, the buyer will insist on the closing payment being made in cash. In large transactions, the seller will have limitations on the ability to liquidate their invested portfolio, and consequently, the buyer will be receiving other invested assets, such as treasury bonds. Depending on the other assets transferred, the buyer may want a pre-closing evaluation of those assets.
Assumption reinsurance transactions are subject to regulatory approval by the domiciliary states of the buyer and the seller. As a result, there is often a gap between the execution of the agreement and the closing. In addition, some states have laws that give policyholders the right to object to the transfer of his or her policy. For those states, more complicated structures must be considered for effecting the transfer of the book of business.
Barry Senterfitt is a partner in the insurance industry practice of Akin Gump Strauss Hauer & Feld LLP, in the firm's Austin, Texas, office.
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More